Dr Lal PathLabs is India's largest diagnostic services player by revenue, with 289 laboratories across the country
In Q4FY22, normalised earnings before interest, taxes, depreciation, and amortization (EBITDA) margins contracted 630 bps to 19.4 per cent from 25.7 per cent in Q4FY21
Operating revenue rose 12.7% during the quarter to Rs 485.5 cr; Covid-19 and allied segments added roughly 13.6% to Q4 top line
The pharma index had taken a breather over the past three months after displaying relative out-performance during CY20-21.